- Home
- HRMY vs CCB Comparison
HRMY vs CCB Comparison
Compare HRMY & CCB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HRMY
- CCB
- Stock Information
- Founded
- HRMY 2017
- CCB 1997
- Country
- HRMY United States
- CCB United States
- Employees
- HRMY N/A
- CCB N/A
- Industry
- HRMY Biotechnology: Pharmaceutical Preparations
- CCB Major Banks
- Sector
- HRMY Health Care
- CCB Finance
- Exchange
- HRMY Nasdaq
- CCB Nasdaq
- Market Cap
- HRMY 1.5B
- CCB 1.8B
- IPO Year
- HRMY 2020
- CCB 2018
- Fundamental
- Price
- HRMY $31.40
- CCB $105.50
- Analyst Decision
- HRMY Strong Buy
- CCB Strong Buy
- Analyst Count
- HRMY 9
- CCB 4
- Target Price
- HRMY $50.44
- CCB $113.75
- AVG Volume (30 Days)
- HRMY 912.0K
- CCB 108.0K
- Earning Date
- HRMY 11-04-2025
- CCB 10-29-2025
- Dividend Yield
- HRMY N/A
- CCB N/A
- EPS Growth
- HRMY 50.44
- CCB 6.80
- EPS
- HRMY 3.17
- CCB 3.17
- Revenue
- HRMY $825,944,000.00
- CCB $342,476,000.00
- Revenue This Year
- HRMY $20.68
- CCB $90.18
- Revenue Next Year
- HRMY $15.93
- CCB $25.38
- P/E Ratio
- HRMY $9.92
- CCB $33.49
- Revenue Growth
- HRMY 21.13
- CCB 25.19
- 52 Week Low
- HRMY $25.52
- CCB $68.53
- 52 Week High
- HRMY $40.93
- CCB $119.22
- Technical
- Relative Strength Index (RSI)
- HRMY 63.59
- CCB 47.23
- Support Level
- HRMY $27.66
- CCB $103.69
- Resistance Level
- HRMY $30.96
- CCB $108.31
- Average True Range (ATR)
- HRMY 1.25
- CCB 3.52
- MACD
- HRMY 0.54
- CCB 0.19
- Stochastic Oscillator
- HRMY 92.89
- CCB 27.23
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
About CCB Coastal Financial Corporation
Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company. The maximum revenue of the company is generated from the CCBX segment.